• LOTTE rent-a-car introduces Jeju travel destinations featured in the drama that captivated global viewers
• Enhancing convenience for international travelers by providing dedicated staff for foreign customers and multilingual support
•  Offering various services such as chauffeur-driven rental cars, welcome coupon packs, and free electric vehicle charging

SEOUL, South Korea, April 29, 2025 /PRNewswire/ — As the Netflix series ‘When Life Gives You Tangerines’ receives an enthusiastic response from global viewers, interest in Jeju Island, known as the ‘Hawaii of Korea’ and the backdrop of the drama, is increasing. With the peak travel season to Jeju from March to May, the number of foreign tourists looking to experience the unique nature of Jeju depicted in the drama is on the rise.

Jeju Island has many hidden gems that are difficult to access using public transportation alone, making rental cars essential. LOTTE rent-a-car, South Korea’s No.1 rental car brand, holds the top market share in the Korean rental car market and is the official partner of the global rental car brand Hertz, providing verified services. They offer a systematic service system and multilingual support platform for international customers.

LOTTE rent-a-car Jeju Auto House is located near Jeju International Airport. It is the largest single-location rental car facility in the country, with a fleet of 3,000 vehicles. Operating 365 days a year from 6 AM to 11 PM, it allows customers to pick up or return vehicles conveniently regardless of flight times. The proportion of foreign customers renting from LOTTE rent-a-car in Jeju is increasing every year. As of 2024, foreign customers account for 25.6% of the total customers at LOTTE rent-a-car Jeju Auto House, meaning one in four customers is a foreigner.

For international tourists planning a trip to Jeju in the first half of this year, LOTTE rent-a-car suggests a special Jeju travel course centered around the filming locations of iconic scenes from the drama. These include Gimnyeong Beach, where young Aesoon eagerly waited for her mother, and Seongsan Ilchulbong, which showcases the beautiful scenery of Jeju.

Gimnyeong Beach: A Pristine Beach Embodying the Lives of female divers

Located in eastern Jeju, Gimnyeong Beach gained attention as the setting for the lives of haenyeo(female divers) in the drama. The exotic landscape, where cobalt blue waters, white sandy beaches, and black basalt rocks harmonize, leaves visitors in awe. Not only can you experience the local haenyeo culture, but you can also enjoy various marine activities such as yachting, kayaking, and snorkeling. The walking trail along the wind turbines lined up on the eastern side of the beach and the nearby cave exploration course add a unique charm.

Seongsan Ilchulbong: A UNESCO World Heritage Site and Sunrise Spot

Seongsan Ilchulbong, where the protagonist Aesoon performs 3,000 bows in the drama, is one of Jeju’s most iconic natural landmarks. Formed by underwater volcanic activity about 5,000 years ago, its cratered terrain is notable. This site is recognized as a UNESCO World Natural Heritage due to its geological significance and is also famous for its breathtaking sunrise views over the open sea. The magnificent scenery, where the blue sea and cliffs blend, leaves a lasting impression on both drama fans and general tourists.

Ora-dong Buckwheat Field: A Healing Photo Spot with Different Faces Each Season

The buckwheat flower path where Aesoon and Gwansik shared memories in the drama was filmed in the buckwheat fields of Ora-dong, Jeju City. The vast field, equivalent to 130 soccer fields, offers different charms each season, making it an ideal photo spot, especially for wedding photos. In spring, yellow canola flowers, in summer, pure white buckwheat flowers adorn the field, and from late winter to spring, the landscape is filled with green barley and reeds. May and June are the best times to witness the most splendid scenery.

Jejumok Gwana: Where Aesoon and Gwansik Wrote Poems for the Writing Contest

Jejumok Gwana is where the writing contest in the drama took place. It was the administrative center of Jeju during the Joseon Dynasty and is a nationally designated heritage site and a representative historical and cultural tourist attraction in Jeju. Aesoon and Gwansik sat in front of Yeonhuijeong Pavilion in this Gwana to write poems. It is also the place where the middle-aged Aesoon wrote a poem longing for her mother. Recently, it has become very popular among foreign tourists, as they can rent hanbok(traditional Korean clothing) from nearby rental shops. It is common to see tourists taking photos in hanbok in front of the traditional Korean houses.

LOTTE rent-a-car Welcomes Foreign Customers with Professional Staff, Coupon Packs, and Electric Vehicle Promotions

LOTTE rent-a-car operates professional staff who can provide consultations in foreign languages. The official website supports English, Chinese, and Japanese, allowing international customers to smoothly handle the entire process from vehicle reservation to contract management and consultation in their native language. This makes it easy for first-time visitors to Korea to use the rental car service.

For tourists who find driving on unfamiliar roads burdensome or have a lot of luggage, it is recommended to use the chauffeur service. Professional drivers familiar with the local road conditions will drive, allowing tourists to focus solely on the beautiful scenery of Jeju outside the window. A variety of vehicle types are available, from compact cars to vans, SUVs, and 11-seater and 15-seater vehicles. This service can be used upon reservation inquiry.

There are also various benefits provided to international tourists using LOTTE rent-a-car. The ‘Jeju Welcome Coupon Pack,’ which consists of benefits necessary for traveling in Jeju, is a new free service offered to customers using LOTTE rent-a-car’s short-term rental cars in Jeju. It provides discounts of up to 54% on popular tourist attractions in Jeju and LOTTE affiliates. A free charging promotion that provides a charging card for electric vehicle users is also being implemented for international customers. Jeju’s major tourist attractions are well-equipped with electric vehicle charging infrastructure, making it convenient to use electric vehicles.

LOTTE rental, stated, “We will continue to expand various customized services so that travelers from around the world can experience the beauty and sentiment of Jeju more conveniently,” adding, “LOTTE rent-a-car will continue to enhance trust and satisfaction as a brand that accompanies the journeys of global customers.”

LOTTE rental is South Korea’s leading rental company, providing integrated rental solutions across all fields, including automobiles, office automation equipment and industrial equipment. Its subsidiary, LOTTE rent-a-car, holds the top market share in the domestic rental car industry and offers extensive mobility services to domestic and international customers through over 220 branches nationwide and a global partnership network.

https://www.lotterentacar.net/hp/chn/reservation/index.do?LANG=chn

About LOTTE rental

LOTTE rental, the only comprehensive rental company in Korea, provides better value with various business portfolios, including auto mobility services that encompass car life, business solution services that support more effi­cient businesses.

LOTTE rent-a-car is creating an innovative car life as the No.1 car rental brand. LOTTE rent-a-car G car, Korea’s ‑first car-sharing brand, is drawing a better mobility service.

LOTTE rental is moving forward as a mobility leader that connects customers’ precious lives.

For more information about LOTTE rental, please visit: https://www.lotterental.com/

 HONG KONG, April 29, 2025 /PRNewswire/ — Dalton Venture CEO Summit 2025 , jointly hosted by Dalton Venture and Hong Kong Science and Technology Parks Corporation (HKSTP), successfully concluded at Hong Kong Science Park. The summit brought together over 100 distinguished guests, including government officials, leading scholars, entrepreneurs, and investors from Mainland China, Hong Kong, and beyond, to explore new global opportunities in life sciences innovation.

The event gathered more than 60 entrepreneurs from Dalton Venture’s portfolio companies across cutting-edge sectors such as cell and gene therapy, ophthalmology, AI in healthcare, embodied AI, bio-3D-printing, and cardiovascular technologies.

Uniting Industry, Research, and Capital to Accelerate Globalization

Founding Managing Partner Sun Qi highlighted Hong Kong’s unique advantages as an East-West bridge, with world-class research infrastructure and capital markets. “Dalton Venture sees Hong Kong not only as a gateway to the world but as a convergence point for technology, capital, industry, and vision,” as he said.

Ms. Cheong Man Lei, Lillian, JP, Deputy Secretary for Innovation, Technology and Industry of the Hong Kong SAR Government, delivered a video keynote address. She emphasized Hong Kong’s commitment to becoming an international innovation and technology hub, citing initiatives like the HK$10 billion Research, Academic and Industry Sectors One-plus Scheme. She warmly welcomed more Mainland Chinese enterprises to leverage Hong Kong’s platform for international expansion.

Hong Kong Science Park as a Launchpad for Life Sciences Innovation

Ms. Gracie Ng, Chief of Staff and Acting Chief Corporate Development Officer of HKSTP, also extended a warm welcome. She highlighted HKSTP’s role in cultivating a vibrant life sciences ecosystem through research support, incubation services, and funding channels, including its HK$1 billion corporate venture fund. “We are delighted to host Dalton Venture’s CEO Summit and look forward to deepening collaboration with visionary enterprises.”

Capital Empowering Innovation: Insights from HKEX

Sam S.K. Luk, Vice President (Global Issuer Services) at Hong Kong Exchanges and Clearing Limited (HKEX), outlined Hong Kong’s latest initiatives to support biotech and hard-tech enterprises through listing mechanisms like Chapter 18A and 18C. He emphasized that Hong Kong remains a preferred destination for innovative companies seeking global investors, citing recent resilience in the local stock market and continued inflows from Southbound trading under the Stock Connect program.

Thought Leadership on Frontier Technologies

The summit also featured keynote speeches from leading scientists and entrepreneurs.

Professor Lam Hon Ming, Distinguished Professor of Life Sciences at The Chinese University of Hong Kong, and Director of the State Key Laboratory of Agrobiotechnology shared insights on agricultural biotechnology and sustainability.

Professor Sirui Han, representing Professor Guo Yike, Chief Vice President of the Hong Kong University of Science and Technology and Director of the Hong Kong Center for Generative Artificial Intelligence Research and Development, discussed the evolution of large AI models and their transformative impact on life sciences.

Strengthening Cross-Border Innovation Bridges

Prior to the summit, Dalton Venture organized a closed-door dialogue with InvestHK and the Office for Attracting Strategic Enterprises (OASES), connecting over 30 Mainland biotech companies with Hong Kong’s innovation and policy resources. Discussions focused on leveraging Hong Kong as a springboard for global clinical development, regulatory pathways, and international fundraising.

Looking Ahead: Building a Global Innovation Network

Mr. Huang Ning, Founding Partner of Dalton Venture, concluded the summit by reaffirming Dalton’s commitment to empowering entrepreneurs and accelerating the globalization of life sciences innovation.

As innovation continues to reshape the life sciences sector, Dalton Venture remains dedicated to fostering a robust, interconnected ecosystem that links research, capital, and industry across borders — advancing healthcare for a better future.

CONTACT
Name: Lynn Ning
Email: ningx@daltonventure.cn

New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent

MELBOURNE, Australia, April 29, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET^[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in France by ANSM^[2] for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label.

Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings:

• Primary staging of patients with high-risk PCa prior to primary curative therapy.
• Suspected recurrent PCa in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy.
• Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer (mCRPC) for whom PSMA-targeted therapy is indicated.

PSMA-PET^[3] imaging represents a significant advancement in prostate cancer management, providing clinicians with more information than conventional imaging methods (bone scan, CT^[4] scan) thereby offering a new standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines recognise its superior accuracy in staging primary disease and assessing BCR/biochemical persistence (BCP)^[5]. Illuccix® PSMA-PET will help address an important clinical need by supporting timely and effective diagnosis, as well as identifying patients who may benefit from PSMA-targeted therapy.

Illuccix’s broad approval is supported by robust clinical data, including the largest Ga-68-based PSMA data set from the VISION trial^[6]. The approval of Illuccix® in France has the potential to resolve access challenges by enabling hospitals and clinics to prepare PSMA-PET scans on-site, offering physicians a quicker, more accessible solution.

Professor Frédéric Courbon, Head of the Medical Imaging Department – University Cancer Institute of Toulouse – Oncopole, commented, “PSMA-PET imaging is dramatically changing prostate cancer patient management. Thus, equitable and reliable access to PSMA-PET across France is essential.The approval of Illuccix® in France will address some of the access challenges, and reduce the risk of delayed diagnosis, with a readily available option for effective disease management.”

With its broad indication and ready-to-use formulation, Illuccix® is designed to support healthcare providers in delivering efficient and reliable imaging. The approval comes as demand for PSMA-PET continues to grow across Europe, reinforcing the need for solutions that fit within existing hospital workflows.

“The approval of Illuccix in France will enable a clinically validated PSMA-PET product to be more widely available, allowing healthcare providers to benefit from the convenience and flexibility of generator-produced gallium. This milestone reinforces our ongoing commitment to advancing prostate cancer care and expanding access to innovative diagnostic technologies across Europe,” said Raphaël Ortiz, Chief Executive Officer, Telix International.

Telix will partner with IRE ELiT S.A. (the radiopharmaceutical subsidiary of IRE Group), a leading provider of radioisotopes and radiopharmaceuticals for nuclear medicine, for the marketing and promotion of Illuccix® to healthcare professionals in France.

Jean Bonnet, Head of Strategy, Sales and Marketing, IRE EliT added: “We are pleased to collaborate with Telix and bring our expertise to expanding the availability of Illuccix throughout France. We are committed to ensuring that clinicians have access to reliable PSMA-PET imaging technologies to improve the lives of people living with prostate cancer.”

– ENDS –

Notes to editors

• French healthcare professionals interested in ordering Illuccix® or learning more about availability can contact Eric Rizzo: eric.rizzo@ire-elit.eu 

Prostate Cancer in France

Prostate cancer is the most common cancer in men in France, with over 57,000 new cases diagnosed annually, and a significantly higher incidence in men than either lung cancer (32,800 new cases) or bowel cancer (27,000 new cases). Prostate cancer is also a common cause of cancer death in men, with over 9,200 men dying from their disease in France in 2022^[7].

About Illuccix®  

Telix’s prostate imaging product, gallium-68 (⁶⁸Ga) gozetotide injection (also known as ⁶⁸Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)^[8], by the Australian Therapeutic Goods Administration (TGA)^[9], by Health Canada^[10], by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA)^[11], by the French ANSM, and in multiple other European Economic Area (EEA) Member States^[12]. Illuccix® is currently in national approval review across the European Economic Area following a positive decentralized procedure (DCP) opinion by BfArM^[13].

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Telix’s osteomyelitis (bone infection) imaging agent, technetium-99m (^99mTc) besilesomab, marketed under the brand name Scintimun®, is approved in 32 European countries and Mexico. Telix’s miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area. No other Telix product has received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.

SINGAPORE, April 29, 2025 /PRNewswire/ — EDXM Global today announced the formation of its Board of Directors, appointing industry leaders Rakesh Madamanchi, Peter Colven and Ramesh Arumugam as Board Directors. They collectively bring extensive expertise in trading infrastructure, operations and compliance, and will support CEO Kai Kono as EDXM Global expands institutional adoption of its digital asset trading venue.

Madamanchi joins the Board with an established track record in risk management and regulatory affairs. He has served as EDXM Global’s Chief Compliance Officer since May 2024 and brings over 18 years of experience across global financial institutions, including Blockchain.com, Wells Fargo, ANZ and Standard Chartered Bank to the Board.

Colven joins the Board as a Non-Executive Director. He is the APAC Chief Operating Officer at Citadel, where he oversees key corporate functions in the region. He brings extensive operational expertise to the Board, including over two decades of experience at Goldman Sachs across London, Tokyo and Hong Kong offices, where he worked in senior roles, including Chief Operating Officer and Chief Risk Officer in Global Markets for APAC.

Arumugam joins the Board as a Non-Executive Director. He is the APAC Managing Director at Virtu Financial. He joined the firm in 2020 as Head of Business Development in Asia, leading business development and expanding institutional access to high-speed, low-latency trading platforms. Prior to this, he held key roles at NYSE Euronext’s fintech division and SGX, where he led clearing and trading sales across global markets. Arumugam’s business development experience will support EDXM Global as it accelerates its expansion in the region.

“We are honored to welcome Rakesh, Peter and Ramesh to our Board of Directors as we serve our growing roster of institutional clients,” said Kai Kono, CEO of EDXM Global. “Each brings a wealth of proven leadership and operational expertise across global financial markets. Their guidance will be instrumental as we scale our infrastructure and further deepen institutional access to digital assets.”

About EDXM Global

EDXM Global is a fast-growing digital asset trading venue for institutional clients that leverages best practices from traditional financial markets on a purpose-built crypto platform. Based in Singapore, EDXM Global’s robust liquidity environment, modern technology and nonconflicted business model are designed to meet the needs of both crypto-native firms and the world’s largest financial institutions. EDXM Global is a subsidiary of EDX Markets Holding Company Inc.

About EDX

EDX is a digital asset technology firm that combines an institution-only trading venue with a central clearinghouse. EDX Markets, our flagship marketplace, is designed to emulate the world’s most sophisticated exchanges, with deep liquidity, firm prices and low trading costs. EDX has structured its business to minimize risk for its members while providing a diverse array of operational and capital efficiencies. Backed by some of the world’s leading trading and venture capital firms, EDX is actively developing new features and expanding its geographic presence to deliver trusted, liquid and efficient crypto trading experiences for all institutions. To learn more, visit edxmarkets.com.

Media Contact

For further information and interviews with Kai Kono:
press@edxmglobal.com | +61 416 219 358

Disclaimer: EDXM Global’s products and services are only available to non-US persons and non-US institutions in select jurisdictions.